{"id":"https://openalex.org/W2856466152","doi":"https://doi.org/10.1007/s10637-018-0636-3","title":"A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma","display_name":"A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma","alternate_titles":[],"publication_year":2018,"publication_date":"2018-07-11","ids":{"openalex":"https://openalex.org/W2856466152","doi":"https://doi.org/10.1007/s10637-018-0636-3","mag":"2856466152","pmid":"https://pubmed.ncbi.nlm.nih.gov/29995286","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6510840"},"language":"en","primary_location":{"id":"doi:10.1007/s10637-018-0636-3","doi":"https://doi.org/10.1007/s10637-018-0636-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s10637-018-0636-3","pdf_url":"https://link.springer.com/content/pdf/10.1007%2Fs10637-018-0636-3.pdf","source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2856466152"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007%2Fs10637-018-0636-3.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022537134","display_name":"Masafumi Ikeda","orcid":"https://orcid.org/0000-0002-4050-2086","observed_orcids":["https://orcid.org/0000-0002-4050-2086"]},"institutions":[{"id":"https://openalex.org/I4210145079","display_name":"National Cancer Center Hospital East","ror":"https://ror.org/03rm3gk43","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210145079"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Masafumi Ikeda","raw_affiliation_strings":["National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan. masikeda@east.ncc.go.jp","National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan"],"raw_orcid":"https://orcid.org/0000-0002-4050-2086","affiliations":[{"raw_affiliation_string":"National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan. masikeda@east.ncc.go.jp","institution_ids":["https://openalex.org/I4210145079"]},{"raw_affiliation_string":"National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan","institution_ids":["https://openalex.org/I4210145079"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101457577","display_name":"Manabu Morimoto","orcid":"https://orcid.org/0000-0002-3940-9634","observed_orcids":["https://orcid.org/0000-0002-3940-9634","https://orcid.org/0009-0006-7576-7187"]},"institutions":[{"id":"https://openalex.org/I4387152949","display_name":"Kanagawa Cancer Center","ror":"https://ror.org/00aapa202","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4387152949"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Manabu Morimoto","raw_affiliation_strings":["Kanagawa Cancer Center, Yokohama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kanagawa Cancer Center, Yokohama, Japan","institution_ids":["https://openalex.org/I4387152949"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081007817","display_name":"Masaomi Tajimi","orcid":"https://orcid.org/0000-0001-5815-377X","observed_orcids":["https://orcid.org/0000-0001-5815-377X"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Masaomi Tajimi","raw_affiliation_strings":["Eli Lilly Japan K.K, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Koichi Inoue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Koichi Inoue","raw_affiliation_strings":["Eli Lilly Japan K.K, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006585898","display_name":"Karim Adnane Benhadji","orcid":"https://orcid.org/0000-0001-9883-6970","observed_orcids":["https://orcid.org/0000-0001-9883-6970"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karim A. Benhadji","raw_affiliation_strings":["Eli Lilly and Company, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, New York, NY, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033549340","display_name":"Michael Lahn","orcid":"https://orcid.org/0000-0002-1377-7308","observed_orcids":["https://orcid.org/0000-0002-1377-7308"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael M. F. Lahn","raw_affiliation_strings":["Formerly Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Formerly Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101675553","display_name":"Daisuke Sakai","orcid":"https://orcid.org/0000-0002-9436-7553","observed_orcids":["https://orcid.org/0000-0002-9436-7553"]},"institutions":[{"id":"https://openalex.org/I4210155576","display_name":"Osaka University Hospital","ror":"https://ror.org/05rnn8t74","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210155576","https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daisuke Sakai","raw_affiliation_strings":["Osaka University Hospital, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University Hospital, Osaka, Japan","institution_ids":["https://openalex.org/I4210155576"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5022537134"],"corresponding_institution_ids":["https://openalex.org/I4210145079"],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":{"value":4690,"currency":"USD","value_usd":4690},"fwci":2.5793,"has_fulltext":true,"cited_by_count":50,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.89988969,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"37","issue":"1","first_page":"118","last_page":"126"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10966","display_name":"Liver physiology and pathology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/galunisertib","display_name":"galunisertib","score":1.0},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9819999933242798},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9449999928474426},{"id":"https://openalex.org/keywords/unresectable-liver-cancer","display_name":"unresectable liver cancer","score":0.859000027179718},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8130000233650208},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7649999856948853},{"id":"https://openalex.org/keywords/hypophosphatemia","display_name":"hypophosphatemia","score":0.925000011920929},{"id":"https://openalex.org/keywords/palmar-plantar-erythrodysesthesia-syndrome","display_name":"palmar-plantar erythrodysesthesia syndrome","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8059999942779541},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.878000020980835},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.9070000052452087}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.897707462310791},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8784801959991455},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8016195297241211},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.6924220323562622},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6679385900497437},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6356030702590942},{"id":"https://openalex.org/C2778573388","wikidata":"https://www.wikidata.org/wiki/Q1641384","display_name":"Hypophosphatemia","level":2,"score":0.6157245635986328},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5116079449653625},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.48083624243736267},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4435109794139862},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41878628730773926}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077293","descriptor_name":"Receptor, Transforming Growth Factor-beta Type I","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s10637-018-0636-3","doi":"https://doi.org/10.1007/s10637-018-0636-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s10637-018-0636-3","pdf_url":"https://link.springer.com/content/pdf/10.1007%2Fs10637-018-0636-3.pdf","source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5504761","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6510840","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6510840","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6510840/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Invest New Drugs","raw_type":"Text"},{"id":"pmid:29995286","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29995286","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational new drugs","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1007/s10637-018-0636-3","doi":"https://doi.org/10.1007/s10637-018-0636-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s10637-018-0636-3","pdf_url":"https://link.springer.com/content/pdf/10.1007%2Fs10637-018-0636-3.pdf","source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2856466152.pdf","grobid_xml":"https://content.openalex.org/works/W2856466152.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1565561072","https://openalex.org/W1948417349","https://openalex.org/W1970293698","https://openalex.org/W1971837077","https://openalex.org/W1982734162","https://openalex.org/W1994193851","https://openalex.org/W2018867485","https://openalex.org/W2029098899","https://openalex.org/W2037038224","https://openalex.org/W2045626840","https://openalex.org/W2079586464","https://openalex.org/W2106787323","https://openalex.org/W2117225762","https://openalex.org/W2197145779","https://openalex.org/W2278888725","https://openalex.org/W2344682920","https://openalex.org/W2608573151","https://openalex.org/W2737832318","https://openalex.org/W2917837889","https://openalex.org/W2962221292","https://openalex.org/W3139763557","https://openalex.org/W4324262440"],"related_works":["https://openalex.org/W2962221292","https://openalex.org/W2737832318","https://openalex.org/W2751641648","https://openalex.org/W2608573151","https://openalex.org/W2937730750","https://openalex.org/W1948417349","https://openalex.org/W3109308944","https://openalex.org/W2561479470","https://openalex.org/W2560484009","https://openalex.org/W4251768114"],"abstract_inverted_index":{"Background":[0],"Galunisertib":[1,65],"inhibits":[2],"type":[3],"I":[4],"transforming":[5],"growth":[6],"factor-beta":[7],"receptor":[8],"serine/threonine":[9],"kinase.":[10],"The":[11,96,135,160,185],"primary":[12],"objective":[13],"of":[14,24,49,53,83,188,209,241,245],"this":[15],"study":[16,47],"was":[17,71,100,194],"to":[18,196],"evaluate":[19],"the":[20,104,230,242],"safety":[21,232],"and":[22,38,110,125,153,172,212,236,238],"tolerability":[23,240],"galunisertib":[25,121,189,235,246],"in":[26,30,59,190,254,258],"combination":[27,60,191,255],"with":[28,33,61,192,229,256,261],"sorafenib":[29,62,86,193,237,257],"Japanese":[31,259],"patients":[32,145,151,158,170,177,203,260],"unresectable":[34,262],"hepatocellular":[35,220,263],"carcinoma.":[36,264],"Patients":[37],"methods":[39],"This":[40],"open-label,":[41],"dose-escalation,":[42],"multicenter,":[43],"nonrandomized":[44],"phase":[45],"1b":[46],"consisted":[48],"two":[50],"dose":[51,244],"levels":[52],"galunisertib,":[54],"160":[55],"or":[56,68],"300":[57],"mg/day,":[58],"800":[63],"mg/day.":[64],"80":[66],"mg":[67,70,88,248],"150":[69],"administered":[72,89],"orally":[73,90],"twice":[74,91,249],"daily":[75,92,250],"for":[76,93,132,200,234,251],"14":[77,81,252],"days":[78,82,102],"followed":[79],"by":[80,219],"rest":[84],"plus":[85],"400":[87],"28":[94,101],"days.":[95],"dose-limiting":[97,128],"toxicity":[98],"evaluation":[99],"after":[103],"first":[105],"dose.":[106],"Safety":[107],"measures,":[108],"pharmacokinetics,":[109],"antitumor":[111],"activity":[112],"were":[113,123,130,142,167,183],"assessed.":[114],"Results":[115],"Fourteen":[116],"patients,":[117],"7":[118],"at":[119],"each":[120],"dose,":[122],"enrolled":[124],"treated.":[126],"Three":[127],"toxicities":[129],"reported":[131,199],"2":[133],"patients.":[134],"most":[136,161],"common":[137,162],"treatment-emergent":[138],"adverse":[139],"events":[140],"(TEAEs)":[141],"hypophosphatemia":[143,168],"(14":[144],"[100%]),":[146],"palmar-plantar":[147,173],"erythrodysesthesia":[148,174],"syndrome":[149,175],"(12":[150],"[85.7%]),":[152],"decreased":[154],"platelet":[155],"count":[156],"(10":[157,169],"[71.4%]).":[159],"grade":[163,180],"\u2265":[164],"3":[165],"TEAEs":[166,182],"[71.4%])":[171],"(7":[176],"[50.0%]).":[178],"No":[179],"5":[181],"reported.":[184],"pharmacokinetic":[186],"profile":[187,233],"similar":[195],"that":[197],"previously":[198],"galunisertib.":[201],"Eleven":[202],"had":[204],"a":[205,216],"best":[206],"overall":[207],"response":[208,218],"stable":[210],"disease,":[211],"1":[213],"patient":[214],"achieved":[215],"partial":[217],"carcinoma-specific":[221],"modified":[222],"RECIST.":[223],"Conclusions":[224],"These":[225],"data":[226],"are":[227],"consistent":[228],"known":[231],"confirm":[239],"recommended":[243],"(150":[247],"days)":[253]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2856466152","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2018-07-19T00:00:00"}
